Novavax
United States
837 articles about Novavax
-
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
5/12/2023
Novavax, Inc. announced that the Singapore Health Sciences Authority has granted extended interim authorization and the Ministry of Health has included Nuvaxovid™ into the National Vaccination Programme as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID.
-
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
5/9/2023
Novavax, Inc. announced that its COVID-Influenza Combination, stand-alone influenza and high-dose COVID vaccine candidates all showed a reassuring preliminary safety profile as well as comparable reactogenicity to individual Novavax influenza and COVID vaccine candidates or authorized influenza vaccine comparators.
-
Novavax Reports First Quarter 2023 Financial Results and Operational Highlights
5/9/2023
Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced its financial results and operational highlights for the first quarter ended March 31, 2023.
-
The layoffs come as the company posts nearly $300 million in net losses and just over $80 million in revenue during the first quarter of 2023. -
Novavax to Participate in the BofA Securities 2023 Health Care Conference
5/4/2023
Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced that it will participate in the BofA Securities 2023 Health Care Conference.
-
Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023
5/2/2023
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its first quarter 2023 financial results and operational highlights at 8:30 a.m. EDT on Tuesday, May 9, 2023.
-
At the World Vaccine Congress this week, Novavax presented data suggesting that its protein nanoparticle booster generated immune responses that could protect against severe infection. -
Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases
4/4/2023
Novavax, Inc. (Nasdaq: NVAX) will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC, April 3 to 6, 2023, and the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023.
-
The Rise, Fall and Future of Novavax
3/21/2023
On Feb. 28, Novavax issued a candid warning to investors: it may not be able to continue operations beyond February 2024. BioSpace takes a deep dive into the vaccine maker's prospects. -
Novavax to Participate in TD Cowen's 43rd Annual Health Care Conference
3/6/2023
Novavax, Inc. today announced that it will participate in TD Cowen's 43rd Annual Health Care Conference.
-
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) - March 02, 2023
3/2/2023
Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced that the Company granted a non-qualified stock option and restricted stock units to Elaine O'Hara, its newly appointed Chief Strategy Officer, as a material inducement for her entry into employment with Novavax, effective as of March 1, 2023.
-
Novavax expressed doubts about its ability to continue operations beyond this year in its Q4 and full year 2022 financial report issued Tuesday.
-
Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
2/28/2023
Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2022.
-
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023
2/21/2023
Novavax, Inc., a global vaccines company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced it will report its fourth quarter and full year 2022 financial results and operational highlights on Tuesday, February 28, 2023, following the close of U.S. financial markets.
-
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
2/13/2023
Novavax, Inc. (Nasdaq: NVAX) today announced a modification to its existing agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, to deliver up to 1.5 million doses of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373).
-
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) - Jan 25, 2023
1/25/2023
Novavax, Inc. announced that it has granted a non-qualified stock option and restricted stock units to John C. Jacobs, its newly appointed President and Chief Executive Officer, as a material inducement for his entry into employment with Novavax, effective as of January 23, 2023, the first date of his employment with Novavax.
-
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
1/18/2023
Novavax, Inc. today announced that partner SK bioscience has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373) for use as a booster for active immunization to prevent COVID-19 in adults aged 18 and older.
-
Novavax Names John C. Jacobs as New President & Chief Executive Officer
1/9/2023
Novavax, Inc. announced that John C. Jacobs will succeed Stanley C. Erck as President and Chief Executive Officer and a member of the Board of Directors.
-
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
12/30/2022
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination and influenza stand-alone vaccine candidates.
-
Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock
12/28/2022
Novavax, Inc. completed the closing of its previously announced offering of $150 million aggregate amount of 5.00% Senior Convertible Notes due 2027, and on December 23, 2022, the Company completed the closing of the initial purchasers' option to purchase up to an additional $25.25 million aggregate principal amount of the Notes, which was exercised in full.